-
摘要: 下尿路功能障碍可由中枢和外周神经系统以及尿路上皮和逼尿肌的病变导致。随着人们对下尿路研究的不断深入，临床上出现多种治疗下尿路功能障碍的新方法和新药物，但是对症状严重的患者效果仍不尽如人意。基因治疗为下尿路功能障碍的治疗提供了一种全新的途径。本文对目前国内外基因治疗在下尿路功能障碍的应用及基因导入载体的种类和优缺点进行综述。Abstract: Lower urinary tract dysfunction is caused by pathophysiological alterations of central and peripheral nervous systems, as well as urothelium and detrusor. Recent researches have increased treatment options thus many new medical care and drugs have emerged for lower urinary tract symptoms. Nevertheless, doctors still experience refractory cases. Gene therapy offer a new therapeutic approach. In this article, we review the current status of gene therapy for lower urinary tract dysfunction and the advantages and disadvantages of gene delivery systems.
-
-
[1] Miyazato M, Sasatomi K, Hiragata S, et al. GABA receptor activation in the lumbosacral spinal cord decreases detrusor overactivity in spinal cord injured rats[J]. J Urol, 2008, 179(3):1178-83.
[2] Miyazato M, Sugaya K, Goins W F, et al. Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats[J]. Gene Ther, 2009, 16(5):660-668.
[3] Miyazato M, Sugaya K, Saito S, et al. Suppression of detrusor-sphincter dyssynergia by herpes simplex virus vector mediated gene delivery of glutamic acid decarboxylase in spinal cord injured rats[J]. J Urol, 2010, 184(3):1204-1210.
[4] Yokoyama H, Sasaki K, Franks M E, et al. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin[J]. Hum Gene Ther, 2009, 20(1):63-71.
[5] Chuang Y C, Chou A K, Wu P C, et al. Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA[J]. J Urol, 2003, 170(5):2044-2048.
[6] Sasaki K, Chancellor M B, Goins W F, et al. Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy[J]. Diabetes, 2004, 53(10):2723-2730.
[7] Liu H T, Kuo H C. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successfulmedical treatment[J]. Urology, 2008, 72(1):104-108.
[8] Kim J C, Kim D B, Seo S I, et al. Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats[J]. BJU Int, 2004, 94(6):915-918.
[9] Chuang Y C, Fraser M O, Yu Y, et al. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor[J]. J Urol, 2001, 165(3):975-979.
[10] Tyagi P, Banerjee R, Basu S, et al. Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates[J]. Mol Pharm, 2006, 3(4):398-406.
[11] Ku J H, Kim Y, Moon K C, et al. In vivo hepatocyte growth factor gene transfer to bladder smooth muscle after bladder outlet obstruction in the rat:a morphometric analysis[J].J Urol, 2006, 176(3):1230-1235.
[12] Keay S. Cell signaling in interstitial cystitis/painful bladder syndrome[J]. Cell Signal, 2008, 20(12):2174-2179.
[13] Erickson D R, Xie S X, Bhavanandan V P, et al. A comparison of multiple urine markers for interstitial cystitis[J]. J Urol, 2002, 167(6):2461-2469.
[14] Ogawa T, Homma T, Igawa Y, et al. CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis[J].J Urol, 2010, 183(3):1206-1212.
[15] Svensson C I, Schafers M, Jones T L, et al. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38[J]. Neurosci Lett, 2005, 379(3):209-213.
[16] Ueda T, Tamaki M, Ogawa O, et al. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T[J]. J Urol, 2000, 164(6):1917-1920.
[17] Oguchi T, Funahashi Y, Yokoyama H, et al. Effect of herpes simplex virus vector-mediated interleukin-4 gene therapy on bladder overactivity and nociception[J]. Gene Ther, 2013, 20(2):194-200.
[18] Funahashi Y, Oguchi T, Goins W F, et al. Herpes simplex virus vector-mediated gene therapy of tumor necrosis factor-a blockade for bladder overactivity and nociception in rats[J]. J Urol, 2013, 189(1):366-373.
[19] Epperly M W, Defilippi S, Sikora C, et al. Radioprotection of lung and esophagus by overexpression of the human manganese superoxide dismutase transgene[J]. Mil. Med, 2002, 167(2 Suppl):71-73.
[20] Epperly M W, Gretton J A, DeFilippi S J, et al. Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy[J]. Radiat Res, 2001, 155(1):2-14.
[21] Kanai A J, Zeidel M L, Lavelle J P, et al. Manganese superoxide dismutase gene therapy protects against irradiation-induced cystitis[J]. Am J Physiol Renal Physiol, 2002, 283(6):F1304-1312.
[22] Christ G J, Day N S, Day M, et al. Bladder injection of "naked" hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo[J]. Am J Physiol Regul Integr Comp Physiol, 2001, 281(5):R1699-1709.
[23] Schrom E M, Moschall R, Schuch A, et al. Regulation of retroviral polyadenylation[J]. Adv Virus Res, 2013, 85(1):1-24.
[24] Kreppel F, Kochanek S. Longterm transgene expression in proliferatingcells mediated by episomallymaintained high-capacity adenovirus vectors[J]. J Virol, 2004, 78(1):9-22.
[25] Goncalves M A, van der Velde I, Knaan-Shanzer S, et al. Stable transuction of large DNA by high-capacity adeno-associated virus/adenovirus hybrid vectors[J]. Virology, 2004, 321(2):287-96.
[26] Bhatia S, Menezes M E, Das S K, et al. Innovative approaches for enhancing cancer gene therapy[J]. Discov Med, 2013, 15(84):309-317.
-
计量
- 文章访问数: 209
- PDF下载数: 127
- 施引文献: 0
下载: